Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trials. However, improvement of their efficacy and sele...

Full description

Bibliographic Details
Main Authors:	Antonio Tapia-Galisteo, Íñigo Sánchez Rodríguez, Oscar Aguilar-Sopeña, Seandean Lykke Harwood, Javier Narbona, Mariola Ferreras Gutierrez, Rocío Navarro, Laura Martín-García, Cesáreo Corbacho, Marta Compte, Javier Lacadena, Francisco J. Blanco, Patrick Chames, Pedro Roda-Navarro, Luis Álvarez-Vallina, Laura Sanz
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Series:	OncoImmunology
Subjects:	trispecific antibodies single-domain antibodies scfv tandem antibodies cancer immunotherapy colorectal cancer
Online Access:	http://dx.doi.org/10.1080/2162402X.2022.2034355

Similar Items

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
by: Antonio Tapia-Galisteo, et al.
Published: (2023-07-01)

Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses
by: Antonio Tapia-Galisteo, et al.
Published: (2024-12-01)

Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity
by: Laura Rubio-Pérez, et al.
Published: (2024-04-01)

Rational Design and Characterization of Trispecific Antibodies Targeting the HIV-1 Receptor and Envelope Glycoprotein
by: Jinhu Liang, et al.
Published: (2023-12-01)

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
by: Ying Cheng, et al.
Published: (2020-11-01)

Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture
by: Jan P. Bogen, et al.
Published: (2021-05-01)

Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
by: Julia Harwardt, et al.
Published: (2023-04-01)

Emerging Antibodies in Cancer Therapy
by: Yaping Sun, et al.
Published: (2023-01-01)

Potent Apoptosis Induction by a Novel Trispecific B7-H3xCD16xTIGIT 2+1 Common Light Chain Natural Killer Cell Engager
by: Michael Ulitzka, et al.
Published: (2024-03-01)

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
by: Stefan Warmuth, et al.
Published: (2021-01-01)

Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
by: Karie Runcie, et al.
Published: (2018-09-01)

Immunotherapy in multiple myeloma
by: Yamna Jadoon, et al.
Published: (2021-01-01)

Engineering multi-specific antibodies against HIV-1
by: Neal N. Padte, et al.
Published: (2018-08-01)

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
by: Zong Sheng Guo, et al.
Published: (2020-07-01)

Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment
by: Valentina Urzì Brancati, et al.
Published: (2023-04-01)

Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models
by: Delphine Valente, et al.
Published: (2020-01-01)

Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity
by: Cheng WJ, et al.
Published: (2021-06-01)

NK Cell-Based Immunotherapy in Colorectal Cancer
by: Mariella Della Chiesa, et al.
Published: (2022-06-01)

Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
by: Kristian Daniel Ralph Roth, et al.
Published: (2021-07-01)

Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer
by: Cynthia Rodríguez-Nava, et al.
Published: (2023-06-01)

Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals
by: Manuela Berto Pucca, et al.
Published: (2011-03-01)

A Cassette Vector System for the Rapid Cloning and Production of Bispecific Tetravalent Antibodies
by: Stefanie Claudia Pohl, et al.
Published: (2012-04-01)

“Stapling” scFv for multispecific biotherapeutics of superior properties
by: Lauren E. Boucher, et al.
Published: (2023-12-01)

Discovery and in vitro characterization of a human anti-CD36 scFv
by: Cecilia Mata-Cruz, et al.
Published: (2025-02-01)

Structural Changes in Stx1 Engineering Monoclonal Antibody Improves Its Functionality as Diagnostic Tool for a Rapid Latex Agglutination Test
by: Daniela Luz, et al.
Published: (2018-02-01)

Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review
by: Barbara Frigerio, et al.
Published: (2021-12-01)

Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity
by: Guang-Quan Liang, et al.
Published: (2020-12-01)

Antibodies on demand: a fast method for the production of human scFvs with minimal amounts of antigen
by: Casal J Ignacio, et al.
Published: (2011-06-01)

Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform
by: Lukas Pekar, et al.
Published: (2020-01-01)

Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy
by: Pedro Roda-Navarro, et al.
Published: (2020-01-01)

Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment
by: Javier Narbona, et al.
Published: (2023-06-01)

Antibody-Mediated Inhibition of Insulin-Degrading Enzyme Improves Insulin Activity in a Diabetic Mouse Model
by: Ofir Fursht, et al.
Published: (2022-03-01)

Phage Display for the Generation of Antibodies for Proteome Research, Diagnostics and Therapy
by: Michael Hust, et al.
Published: (2011-01-01)

Single-step colony assay with autoinduction of scFv expression for the screening of antibody libraries
by: Mieko Kato, et al.
Published: (2019-04-01)

Recombinant single chain variable fragment antibodies (scFv) against Pro(144)-Leu(155) fragment of human protein C
by: O. S. Oliinyk, et al.
Published: (2015-04-01)

Generation and diversification of recombinant monoclonal antibodies
by: Keith F DeLuca, et al.
Published: (2021-12-01)

PRODUCTION OF A HUMAN RECOMBINANT ANTIBODY AGAINST SEROTYPE A CANDIDA ALBICANS
by: A A. Jafari
Published: (2005-07-01)

PRODUCTION OF A HUMAN RECOMBINANT ANTIBODY AGAINST SEROTYPE A CANDIDA ALBICANS
by: A A. Jafari
Published: (2005-08-01)

Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
by: Lin Yu, et al.
Published: (2021-06-01)

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation
by: Oana Hangiu, et al.
Published: (2025-01-01)